5 citations
,
January 2014 in “Indian Journal of Nephrology” This case report describes a 30-year-old woman with systemic lupus erythematosus who was successfully treated for recurrent hypokalemic periodic quadriparesis after being diagnosed with distal tubular acidosis.
June 2026 in “Pediatric Drugs” This study analyzed systemic treatment patterns in 262 French children with severe alopecia areata, finding that while intravenous corticosteroids were most commonly used initially, treatment effectiveness appeared limited with frequent relapses and a need for prolonged therapy, but without serious adverse events.
This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.
October 2025 in “Frontiers in Medicine” This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.
4 citations
,
May 2025 in “Dermatology and Therapy” This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.